Home » Topics » Regulatory » EMA

EMA
RSS

EMEA withdraws marketing authorization for Protopy in the European Union

Oct. 9, 2008

CHMP recommends variations to marketing authorization of Cancidas

Sep. 30, 2008

CHMP recommends marketing authorization for Azarga in open-angle glaucoma

Sep. 30, 2008

GSK withdraws European MAA for Quintanrix vaccine

Sep. 3, 2008

EMEA presents an update on reports of PML in MS patients treated with Tysabri

Aug. 14, 2008

CHMP recommends marketing authorization for GSK's prepandemic influenza vaccine

July 30, 2008

Anticoagulant Xarelto recommended for approval in E.U.; NDA submitted in U.S.

July 30, 2008

CHMP recommends refusal of Santhera's MAA for Sovrima in Friedreich's ataxia

July 30, 2008

CHMP adopts negative opinion for Howmedica's Opgenra

July 4, 2008

EMEA recommends that product information for Pfizer's Exubera include data on lung cancer

June 19, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
$Silhouette of head and brainwith fractal art$
ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit
BioWorld
Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley Inc. (NASDAQ:ATAI) ended July 16 at...